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The Immune Epitope Database (IEDB) is a free public resource which catalogs
experiments characterizing immune epitopes. To accommodate data from next
generation repertoire sequencing experiments, we recently updated how we capture and
query epitope specific antibodies and T cell receptors. Specifically, we are now storing
partial receptor sequences sufficient to determine CDRs and VDJ gene usage which
are commonly identified by repertoire sequencing. For previously captured full length
receptor sequencing data, we have calculated the corresponding CDR sequences and
gene usage information using IMGT numbering and VDJ gene nomenclature format. To
integrate information from receptors defined at different levels of resolution, we grouped
receptors based on their host species, receptor type and CDR3 sequence. As of August
2018, we have cataloged sequence information for more than 22,510 receptors in
18,292 receptor groups, shown to bind to more than 2,241 distinct epitopes. These
data are accessible as full exports and through a new dedicated query interface. The later
combines the new ability to search by receptor characteristics with previously existing
capability to search by epitope characteristics such as the infectious agent the epitope is
derived from, or the kind of immune response involved in its recognition. We expect that
this comprehensive capture of epitope specific immune receptor information will provide
new insights into receptor-epitope interactions, and facilitate the development of novel
tools that help in the analysis of receptor repertoire data.
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INTRODUCTION
The adaptive immune system in vertebrates has evolved to recognize and combat an ever
changing repertoire of pathogenic organisms such as viruses, bacteria, and parasites. The ability
to recognize this plethora of attackers is vastly due to B and T lymphocytes which express a
highly diverse repertoire of antigen receptors. Both B and T cell receptors are generated through
a stochastic process in which segments from several genes are re-arranged (1). B cell receptors
(BCRs) or antibodies (secreted BCRs) are typically heterodimers of two different proteins, a
heavy and a light chain, while T cell receptors (TCRs) are made up of α and β or γ and
δ chains. Chromosomes encoding the heavy and β chains proteins in every B- and T cells,
respectively, have DNA modules composed of variable (V), diversity (D), joining (J), and constant
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(C) genes. On the other hand, light and α chains are encoded by
modules of V, J, and C genes. For example, the IMGT database (2)
reports 68V, 2 D, 14 J, and 2C genes in the human TCR locus of
the β chain and 54V, 61 J, and 1C genes in the complementary α
chain locus.
The recombination process rearranges one each of these
possible V, D, and J gene segments to be adjacent to each
other. B and T cells with productive rearrangements of the two
chains express BCRs and TCRs on their surface, respectively. The
protein domain encoded by V(D)J recombination in heavy and
light chains is known as the variable domain. This combinatorial
rearrangement process is the key to receptor diversity. Receptor
diversity is further amplified by insertions and deletions at the
junctions between the various gene segments (3).While TCRs are
stable after this initial V(D)J re-arrangement, BCRs can further
mutate due to somatic hypermutations and affinity maturation,
resulting in even higher BCR diversity which is associated with
high affinity with their cognate antigen (4). These processes
ultimately supply the host with a broad array of BCR and TCR
receptors capable of binding to immune epitopes that allow the
immune system to distinguish self from non-self.
The Immune Epitope Database (IEDB) contains data gathered
by manual curation of the scientific literature and through direct
submissions of experimentally identified B- and T-cell epitopes
and MHC ligands (5). As of August 2018, the IEDB has over
462,000 epitopes from over 19,500 manually curated references
and direct submissions. In addition to capturing the identity of
these epitopes, the IEDB also captures a vast array of information
on the host organism in which the epitope is recognized, immune
exposures of the host that led to the epitope recognition, the
type of immune response targeting the epitope, and the epitope
specific TCRs or BCRs/antibodies (Figure 1).
Originally, BCR and TCR sequence information was only
curated in the IEDB if a formal sequence record was available
FIGURE 1 | Information captured in the IEDB. Detailed information related to the immune exposure of the host, type of assay used to test the immune response, and
the reference of the data is captured in the IEDB. Data shown in this figure is from IEDB Assay ID: 1479091.
in GenBank or UniProt. This was nearly exclusively the case for
3D structures of receptor-epitope complexes, as immune receptor
sequencing was expensive and labor intensive. However, with the
advent of next generation receptor sequencing experiments, also
known as Rep-Seq (6), epitope specific BCR and TCR sequences
are increasingly becoming available. The sequence data from such
experiments is typically limited to one of the two receptor chains,
and often targets the highly variable CDR3 (Complementarity
Determining Region 3). Capturing these data appropriately and
making it compatible with the existing full length receptor
sequence data in the IEDB required modifying the IEDB curation
approach and database design, as well as the query and reporting
interfaces. These changes are described in the present article.
CHANGES IN THE IEDB DATABASE
STRUCTURE AND CURATION PROCESS
FOR IMMUNE RECEPTORS
Extension of Information Captured on
Immune Receptors
In the past, IEDB receptor data was captured as part of the B-
and T-cell assay tables, and included the receptor names (e.g.,
OT-2), types (e.g., α/β), isotypes (e.g., IgG4), immunoglobulin
(Ig) domains (e.g., Fab, Fv, Whole antibody) and links to their
sequence records (e.g., UniProt or NCBI accessions) for each
of the chains (Table 1). As pointed out, above, next generation
immune receptor sequencing experiments often provide partial
receptor sequences. To store this information, we added fields
to capture CDR1, CDR2, and CDR3 amino acid sequence
information, as well as VDJ gene usage (Table 1). We used the
IMGT definition for CDRs (7), and followed the WHO-IUIS
nomenclature for VDJ genes (8). As sequencing experiments
often target nucleotide sequences, a field to store them was also
added to the assay table (See Table 1).
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TABLE 1 | Data structure and grouping of captured receptor information.
Data fields Assay receptor Distinct receptor Receptor group
Receptor name PMEL17
Source organism Homo sapiens Homo sapiens Homo sapiens
Sequence identifier Chain1: NCBI:5EU6_D
Chain2: NCBI:5EU6_E
Protein sequence Chain1: MKQEVTQIPAALS…
Chain2: GAGVSQTPSNKVT…
Nucleotide sequence –
Curated Calculated
V gene Chain1: TCRAV21
Chain2: TCRBV7-3
Chain1: TRAV21*01
Chain2: TRBV7-3*01
Chain1: TRAV21*01
Chain2: TRBV7-3*01
D gene – – –
J gene – Chain1: TRAJ53*01
Chain2: TRBJ2-3*01
Chain1: TRAJ53*01
Chain2: TRBJ2-3*01
Receptor type αβ αβ αβ αβ
Chain type Chain1: α
Chain2: β
Chain1: α
Chain2: β
Chain1: α
Chain2: β
Chain1: α
Chain2: β
Variable domain sequence – Chain1:KQEVTQIPA…
Chain2:AGVSQTPSN…
Chain1:KQEVTQIPA…
Chain2:AGVSQTPSN…
CDR1 sequence Chain1:DSAIYN
Chain2:SGHTA
Chain1:DSAIYN
Chain2:SGHTA
Chain1:DSAIYN
Chain2:SGHTA
CDR1 positions – Chain1: 28-33
Chain2: 27-31
CDR2 sequence Chain1:IQSSQRE
Chain2:FQGTGA
Chain1:IQSSQRE
Chain2:FQGTGA
Chain1:IQSSQRE
Chain2:FQGTGA
CDR2 positions – Chain1: 51-57
Chain2: 49-54
CDR3 sequence Chain1: AVLSSGGSNYKLTF
Chain2: ASSFIGGTDTQYF
Chain1: AVLSSGGSNYKLT
Chain2: ASSFIGGTDTQY
Chain1: AVLSSGGSNYKLT
Chain2: ASSFIGGTDTQY
Chain1: AVLSSGGSNYKLT
Chain2: ASSFIGGTDTQY
CDR3 positions – Chain 1: 92-104
Chain 2: 93-104
Receptor data captured from publications is shown in ‘assay receptor’ column (IEDB assay ID: 2723539). The values in distinct receptor column were used for creating distinct receptor
entries by combining receptors from different assays. If variable domain sequence was not available then CDR 1, 2 and 3 sequences were used to create distinct receptors. Similarly,
the values in receptor group column are used for clustering similar distinct receptors in a group.
We wanted to capture the same information on CDRs and
gene usage for receptor data for which full length protein
sequences were previously curated. Thus, we identified CDRs,
their position in the full length sequence, variable domain
sequences and VDJ gene usage from full chain protein sequences
based upon the IMGT numbering scheme (7) using ANARCI
software v1.1 (9). This “calculated” information was stored in the
assay table side by side with the “curated” information provided
by the author if both are available (Table 1). The calculated and
curated receptor information is displayed on the assay details
pages in the IEDB (Figure 2).
Distinct Receptor Identifiers
As we do for epitopes and assays, we wanted to assign numeric
IEDB identifiers to receptors that serve as a stable reference, and
group together all information available for a specific receptor
studied. As an epitope database, the IEDB considers two immune
receptors to be distinct if they have different specificities. For
example, addition of a histidine tag to an antibody is not expected
to significantly change its specificity, so we would want data
from an antibody with and without such a tag to be grouped
together, and want to assign it the same identifier to be able
to interlink such reports. Similarly, differences in the nucleotide
sequences of TCRs that encode for the same amino acid variable
domain are not expected to result in different specificities. Based
on these considerations, we identified the subset of information
in Table 1 that is clearly linked to receptor specificity, namely
the species of the host organism making the receptor, the
receptor type, and the sequence of the variable domain/s. If
the full length variable domain sequence is not available, all
the available CDR sequences are considered. For several values,
such as CDR3 regions, an assay may have both curated data
(which reflects what the author stated to be the CDR3), and
calculated data (which is based on automated analysis of the
full length sequence). If both curated and calculated data are
available and they are in conflict, we prioritize the calculated
information, as it is easier for us to guarantee that it follows
the IMGT numbering scheme. Overall, the rows in “distinct
receptor” column of Table 1 identify the subset of properties
that are used to identify distinct receptor entries, and which are
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FIGURE 2 | Assay receptors. The curated and calculated assay receptor information is displayed side by side on the assay details pages in the IEDB. Data shown in
this figure is from the IEDB Assay ID: 2723539.
FIGURE 3 | Receptor groups. Receptors are grouped based on their type, CDR3 sequence/s and host organism. Next generation repertoire sequencing experiments
can report only a single chain CDR3 sequence for a receptor. Therefore, we group receptors hierarchically in groups with identical single chain CDR3 sequences
(receptor group ID: 11040) which are divided in receptor groups based on CDR3 sequences from the other chain (receptor group ID: 1162 and 1525).
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FIGURE 4 | Capturing engineered, camelid and other special receptor types in
the IEDB. The nanobodies and HCAbs in the IEDB are captures under heavy
and heavy-heavy receptor types. The heavy and light chain variable domains in
the scFv are captured as individual chains under scFv receptor type. The
diabodies are captured as constructs. The heavy and light chain pairs in the
diabodies which bind to two different epitopes are captured as two different
assays.
linked to all assay entries that have receptors that match these
fields.
Receptor Groups
While the definition of distinct receptors interlinks records for
which the same receptor sequence information is given, it keeps
records separate for which information is provided at different
levels of granularity. For example, receptors for which only the
TCR-beta chain is sequenced will be separated from receptors
that have both the TCR-alpha and TCR-beta sequence available.
Given that the CDR3 region of immune receptors is the most
variable and is typically responsible for most contacts of the
receptor with the epitope recognized, we decided to provide
groups of receptor data that share the same CDR3 sequence.
Specifically, we grouped together distinct receptors that had
the same host species, receptor type, and CDR3 sequence/s
(shown in “receptor group” column of (Table 1). This
classification is hierarchical, so that the receptor group
sharing the same TCR-α CDR3 sequence, can be subdivided into
multiple receptor groups based on their TCR-β CDR3 sequence.
Figure 3 illustrates how different distinct receptors are assigned
to receptor groups. All the curated receptors were grouped into
18,292 receptor groups using above mentioned criteria.
Receptor Types: Special Cases
While the majority of vertebrates produce heterodimeric
antibodies with heavy and light chains, camelids (camels, llamas
and alpacas) produce naturally occurring heavy chain only
antibodies devoid of light chains (HCAbs) (10). Similarly, sharks
and other cartilaginous fish produce IgNARs (Immunoglobulin
New Antigen Receptors) which are homodimeric heavy chain
only antibodies (11). These observations have led to the
development of engineered antibodies with a single heavy chain
variable domain, known as VHH or nanobodies. Nanobodies
and other types of antibody and TCR constructs, such as single
chain antibodies (scFv), single chain TCRs (TscFv), single domain
antibodies (sdAbs), and bispecific dual-variable- domain (DVD)
antibodies or diabodies (12, 13), pose additional challenges in
curation of receptor information.
To date, the available camelid and shark HCAbs curated in
the IEDB-3D were engineered single-variable-domain antibodies
(monomeric nanobodies or vNAR), so these were captured
under receptor type “heavy” (Figure 4). ANARCI software
cannot assign variable domain sequences and CDRs to IgNARs,
so we captured IgNARs by manual curation, but were not
able to assign calculated CDRs, gene usage and variable
domains to these receptors. The sdAbs are either heavy or
light chain variable domain antibodies (13). Therefore, they
were captured as receptor type “heavy” or “light.” Engineered
single chain antibodies (scFv) and single chain TCRs (TscFv)
with full length sequences were split into their individual
variable domains (heavy, light, α or β) before populating
the assay table (Figure 4). The receptor type “construct” is
included to capture additional types of engineered antibodies
and TCRs, e.g., engineered bi-specific diabodies. The diabodies
or dual-variable-domain (DVD) antibodies with two pairs
of variable heavy and light domains were also split into
individual pair of heavy and light variable domains. Only
the author specified pair of heavy and light variable domains
in the diabodies that interacts with the epitope were stored
in the assay table. If the 3D structure of a diabody bound
to a single epitope was solved by authors, then the pair of
heavy and light chain variable domains interacting with the
antigen was identified using the IEDB-calculated receptor-
antigen contacts within 4Å atomic distance. If both pairs of
heavy and light chain variable domains were in contact with
two different antigens, then they were stored as two different
receptors.
Re-curation
The process of extending the IEDB database and reviewing
previously captured data resulted in the identification and
correction of curation errors, as well as merging of duplicate
records. We identified cases where the chain sequences were
missing from the 3D data, as well as cases where the chain
type was incorrect. The Ig domains from the 3D assays were
identified based on chain lengths and presence or absence
of the binding chain using an in-house script. The CDR
sequences and their positions were extracted using another in-
house script utilizing outputs from an ANARCI (9) analysis
that assigns IMGT numbering to the receptor chain sequences,
and identifies the chain types (heavy, light, α, and β). Conflicts
between calculated and curated Ig domains and chain types
were resolved by manual re-curation of the articles. We also
identified a few TCR and MHC assays where MHC allele
names did not follow the correct nomenclature or were
insufficiently specified. Such alleles were re-curated using an
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FIGURE 5 | Querying IEDB using antibody or TCR sequences. (A) In the past, user query results in the IEDB were displayed in different tabs named epitopes,
antigens, assays, and references. We added a new results tab for receptors to display different receptor groups corresponding to the user query. (B) All the receptor
information in results can be downloaded using “export results” link in the “receptors” tab. Similarly, more detailed results are downloaded from “assays” tab.
(C) Users can filter any query results by receptor full length protein or CDR sequences using the new receptor search panel. The example shown is to filter results by
antibody (receptor type is BCR heavy-light) heavy chain with “CSYAGGKSLV” as CDR3 sequence.
in-house script to identify the MHC allele based on their
epitope binding groove domains [or G-domain (14)] sequence
identity to known MHC alleles captured in the MRO database
(15). G-domains are composed of α1 and α2 domains in
MHC class I molecules and α1 and β1 domains in MHC
class II molecules, and were identified from MHC chain
sequences using IMGT MHC G-domain numbering (14). These
changes in MHC allele names were verified using manual re-
curation.
Identifying Data for Curation
To date, we have identified 1,604 references having TCR
or antibody sequence information from several strategies.
One ongoing strategy is the introduction of screening all
newly published articles relevant to the IEDB scope for
receptor sequence information during our regular manual
screen step (16). This process was introduced into our
normal workflow, which includes an automated PubMed
query (17) that is run every 2 weeks followed by an
automatic document classifier that excludes articles highly
likely to not have any epitope specific information, and
manually reviewing the remaining articles. We also sought
out public resources that capture information on antibody
or TCR sequences. We searched the ATLAS (18), McPAS
(19), VDJdb databases (20), and the Adaptive Biotechnologies
website for references to journal articles that contain epitope
specific receptor information and downloaded all PubMed
IDs. These identified articles were manually reviewed to
ascertain if the receptors mentioned were epitope specific.
If an article contained such data, we manually curated the
entire article following the established IEDB curation rules
(16). We also screened publications with links to GenBank
entries to determine if the entry is an adaptive immune
receptor utilizing ANARCI to identify TCR and antibody
protein sequences. We then manually screened the associated
publications and curated them when they were found to contain
epitope specific data. We have curated 22,510 of these for
antibody or TCR sequence data and are continuing to curate
the remainder on an ongoing basis. We also added TCR
sequence information to articles having TCR transgenic mice
as the host, wherever clear TCR sequences were available for
these mice. All previously curated assays having 3D structures
were reviewed and receptor sequence data were verified for
accuracy and gene usage, V domains, and CDR3 sequences
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FIGURE 6 | Receptor details. Receptor details are split into 3 sections. (A) The first section is a short summary of receptor group. This section has information on
accessions of receptor chains and PDB IDs of receptor-antigen complexes involving individual receptors from this receptor group, if available. (B) The second section
provides information of individual receptors in the receptor group. This section provides CDR sequences, VDJ gene usage, variable domain sequences and epitopes
which are recognized by each receptor. (C) The last section provides a short summary of epitopes recognized by receptor group including assays and publications,
e.g., an antibody in group ID 651 recognizes two different epitopes from Dengue and one epitope from Zika genome polyproteins.
were calculated. These calculations have been implemented
as an ongoing automated process for all newly curated 3D
structures.
QUERYING IEDB FOR EPITOPE SPECIFIC
ANTIBODIES AND TCRS
Addition of Receptor Specific Query
Interface
To enable queries for receptor data in the IEDB, we added
a new set of parameters to the “refine search results” page
that is available after starting a search from the IEDB home
page. Figure 5C depicts the parameters that are available, which
include limiting results to those where any receptor information
is available, and more specifically querying for receptor type,
such as for α-β chain TCR data or heavy-light chain antibodies.
Moreover, users can search by a CDR sequence or a full length
receptor protein sequence with the added feature of searching for
exact identity or for matches at 60, 70, 80, or 90% identity, as well
as a substring match (Figure 5). Importantly, any such queries
can be combined with the general IEDB search criteria, such
as limiting the results to receptors recognizing viruses, or those
present on T cells producing IL-10 upon epitope recognition.
Report of Receptor Groups Matching Any
IEDB Query
The receptors groups matching any query in the IEDB are
displayed in the newly added “receptor” tab (Figure 5A). This
receptor tab describes receptor group IDs, receptor types,
and their host organisms along with CDR3 sequences. All
information on the receptors pertaining to the query can be
downloaded in the CSV format from “export results” link
on “receptor” tab (Figure 5B). Similarly, detailed query results
including information on assay, immunization, epitopes, and
receptors can be downloaded in the CSV format from “Assays”
tab.
When clicking on the receptor group ID, all data on the
distinct receptors matching this group (organism, receptor type,
CDR3 sequences, and variable domain sequences) are provided
to the users with a comprehensive overview of the data available
within the IEDB for these receptors (Figure 6). All experimental
assays utilizing any given receptor can be retrieved, enabling
full access to all biological activities, immunological responses
and associated cellular phenotypes, binding constants, and 3D
structures available for each receptor, across all epitopes that they
were shown to recognize. For example, the human monoclonal
antibody (receptor group ID: 651) shown in Figure 6 has been
tested against two Dengue virus epitopes and one Zika virus
epitope in a total of 4 neutralization assays, two ELISA qualitative
binding assays and two 3D structural assays with antibody-
antigen complexes (PDB IDs: 4UTB and 5LCV).
Exports of Complete Receptor Datasets
In addition to the targeted query described above, the entire
receptor data in the IEDB can be downloaded from the “Database
Export” option from “More IEDB” drop-down menu on IEDB
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website as a zipped CSV file (http://www.iedb.org/database_
export_v3.php). This export file contains extensive details on
assays, immunization, epitopes, and receptors.
SUMMARY OF EPITOPE SPECIFIC
RECEPTOR CONTENT CAPTURED SO FAR
We curated a total of 22,510 receptors which are known to
bind to 2,241 distinct epitopes in 9,901 assays from 1,604
publications as of August 2018 (Table 2). A total of 4,874
curated chains had full length protein sequences and 5,526 chains
had nucleotide sequences. These 22,510 curated receptors were
grouped into a total of 19,537 distinct receptors (Table 2) with
21,066 distinct chains. The distribution of distinct receptors in
TABLE 2 | Receptor groups.
Category Number of receptors Number of epitopes
Total curated receptors 22,510 2,241
Distinct receptors 19,537
Receptor groups 18,292
TCR groups 16,949 536
BCR groups 1,343 1,714
different organisms is shown in Figure 7.Over 90% of the distinct
receptors were from humans and 8% from mice. A total of 2,319
distinct receptors had paired CDRs. All the distinct receptors
were further clustered into 18,292 receptor groups, out of which
16,949 were for TCR groups and 1,343 were antibody groups.
DISCUSSION
We here report our efforts to better represent epitope specific
BCR and TCR data in the IEDB. As mentioned, this is not the
first such effort. Epitope-specific BCR and TCR sequences have
been curated as a part of 3D structural databases such as IEDB-
3D (21) and IMGT/3Dstructure-DB (22). The Epitome (23),
SabDab (24), and STCRDab (25) databases store information
on 3D antibody-antigen (Ab-Ag) complexes, where the focus of
SabDab and STCRDab is unbound antibody and TCR structures,
respectively. A complementary resource, IMGT database (2),
stores germline sequences of antibodies and TCRs. Recently
published databases, such as VDJdb (20) and McPAS-TCR (19),
are focused on curating CDR3 sequences of TCRs from Rep-
Seq experiments (6). VDJdb stores epitope specific TCR-pMHC
data, while McPAS-TCR curates TCR sequences with their
cognate antigens, and associated pathologies. Many of our design
decisions reported here were informed by inspecting how these
other databases represented immune receptors, and were aimed
FIGURE 7 | Distribution of the available receptors from different organisms. Over 90% of the antigen receptor data in the IEDB are from humans and around 8% from
mice.
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at creating a unifying representation of immune receptor data
that is appropriate across different applications.
The IEDB is the only resource that provides information
related to the host, such as species, gender age, and importantly
what the host was exposed to, infected by or allergic to and
other information relevant to the host’s immune response, such
as which cytokines are produced by T cells or if the antibodies
are neutralizing and so on. With our updated curation scheme,
much more information regarding BCR and TCR receptors can
now easily be linked to the epitopes they bind and the immune
responses associated with them in the IEDB. We have curated
BCR and TCR sequence information from the past articles with
low-throughput data as well as the recent articles with the
high-throughput data, unlike VDJdb and McPAS-TCR databases
which focus on the high-throughput data only. This task was not
without its challenges. While a large amount of sequencing data
has been becoming available in the literature; the vast majority
of this data is not epitope specific. IEDB curators must screen
all such publications related to TCR and antibody data to find
the relevant records that can be curated. In many cases when
receptor data is presented as being epitope specific, the epitope
that it is specific for is not clearly defined. This occurs when
authors sequence a large number of receptors specific to a variety
of epitopes derived from the same pathogen but present CDR3
sequences in tables that do not specify which receptor was bound
to which epitope.
Differences in formatting have also been a challenge as
different authors describe VDJ gene usage using differing
nomenclatures and describe CDR sequences using different
numbering schemes especially for antibodies (26–29). Different
receptor numbering schemes and the author reported CDR
sequences from repertoire sequencing experiments can also
include additional flanking junction region residues as a
part of the CDR which create inconsistencies in storing the
CDR sequences from different sources. Other related receptor
sequence databases provide CDR3 sequences from TCRs with
the conserved flanking anchor residues such as Cys and Phe or
Cys and Trp. Such conserved anchor residues are not present
for CDR1 and CDR2 sequences and also, they are excluded from
the CDR regions in the IMGT numbering scheme. To provide
consistent information based on the IMGT numbering scheme,
we have not included the conserved anchor residues in any CDR
sequences in the IEDB. We expect that as the field matures,
standards for reporting experimental protocol and analysis of
receptor repertoire data such as those developed by the AIRR
community (30, 31) will become widely adopted, and these issues
will resolve over time.
Lastly, a key challenge for the IEDB is to define what identifies
a truly epitope specific receptor. The experimental procedures
used to isolate and sequence receptors can be quite variable
and can result in more or less stringency in what is deemed
“epitope specific.” For example, one author may simply re-
stimulate a PBMC culture with a peptide and sequence and report
all receptors from the culture (low stringency). The use of or lack
of experimental controls also varies widely, with some authors
demonstrating that the epitope specific receptor is not found
in controls, while others may have no such controls. We are in
the process of establishing curation rules for receptor data to
take these variables into account, with the goal of consistent and
accurate receptor curation.
While the field is maturing, the IEDB curation procedures are
adapting. This means that the exact data structure utilized might
change, and the persistence of receptor identifiers cannot yet be
guaranteed. We expect receptor identifiers to be stable by the end
of 2018, and will at that point adhere to FAIR standards (32).
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